Bradley Pharmaceuticals Skin Cancer Screening Tour Helps Save Lives By Encouraging Visits To Dermatologists

Bradley
Pharmaceuticals, Inc. (NYSE: BDY) announced today that The Skin Cancer
Screening Tour, sponsored by Bradley's Doak Dermatologics subsidiary in
partnership with The Skin Cancer Foundation, has screened to date more than
3400 individuals. In addition, the media coverage surrounding the Screening
Tour has helped raise awareness of the importance of visiting a
dermatologist, even beyond the scope of the Tour, for early detection of
skin cancer.


At each stop on the Tour, local dermatologists volunteer their time in
the 38-foot Mobile Diagnosis Vehicle (MDv), custom-built by Doak
Dermatologics, performing free skin cancer examinations in two fully
outfitted exam rooms. To date, almost 40% of those screened were identified
as requiring further medical attention for a cancer-related skin condition.


Among the more than 3400 people screened, participating physicians have
identified the following:


-- 825 people with Actinic Keratosis
Actinic Keratosis (AK) affects 1.3 million people annually. AK is the
most common type of precancerous skin lesion. If left untreated, AK can
lead to Squamous Cell Carcinoma.


-- 94 with Squamous Cell Carcinoma
Squamous Cell Carcinoma (SCC) is a form of skin cancer that affects
200,000 Americans each year. SCCs can spread quickly.


-- 303 with Basal Cell Carcinoma
Basal Cell Carcinoma (BCC) is a common form of skin cancer, affecting
more than 800,000 Americans annually.


-- 37 with Melanoma
Melanoma is the most serious form of skin cancer and has increased more
rapidly than any other form of skin cancer during the past 10 years.
Similar to previously mentioned conditions, if melanoma is diagnosed
and removed early, it is almost 100 percent curable.


Doak created The Skin Cancer Screening Tour in response to the
Company's knowledge of the prevalence of skin cancer, heightened by the
acquisition of a major topical therapy for the precancerous skin condition
Actinic Keratosis. More than 1.3 million people will be diagnosed with skin
cancer this year, and in the US, there are more cases of skin cancer than
breast, prostate, lung and colon cancers combined. Because early detection
and treatment are critical to a positive outcome, Doak launched The Skin
Cancer Screening Tour as a public service.


In addition to carrying out screenings on the MDv, The Skin Cancer
Screening Tour is conducting a skin cancer awareness campaign in major
media outlets across the country, urging people to be screened whether
aboard the MDv or by their local dermatologist. For those who cannot visit
the MDv, Doak has created a website with a full listing of dermatologists
by zip code. To date, information on the Tour has appeared in over 250
newspapers and national magazines and on numerous local TV and radio
stations, enabling millions of people to be exposed to the message. For
example, on May 29, 2006, Bradley President and CEO, Daniel Glassman,
appeared on America Health Radio with Scott Broder to discuss the
importance of regular skin cancer screenings. According to Mr. Broder, this
segment was "one of the most popular and well-received shows ever broadcast
on American Health Radio."















Mr. Glassman stated, "Through its Doak Dermatologics subsidiary,
Bradley is extremely proud to be a part of this important effort to draw
attention to the importance of annual screenings and early detection for
skin cancer. We are particularly grateful to the local dermatologists who
have provided their skill and time to this important initiative. We
recognize there is a skin cancer epidemic, and drawing the public's
attention to the necessity of regular visits to dermatologists is a
critical step in gaining control of it. We believe that the statistics from
this tour show that we are helping to generate important awareness, and
encouraging people to visit their dermatologist."


The MDv has conducted screenings in San Francisco; Los Angeles;
Phoenix; Dallas; Houston; Tampa; Miami; West Palm Beach; Atlanta;
Nashville; Avalon, New Jersey; Chicago; and is currently at locations in
Washington, DC, including the Pentagon. The Tour will be traveling through
the Northeastern US during the second half of 2006 and will be extended
into 2007.


To learn more about The Skin Cancer Screening Tour and find a list of
upcoming stops, please visit skincancerscreeningtour.


Please visit Bradley Pharmaceuticals web site at: bradpharm
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.


Bradley Pharmaceuticals, Inc. (NYSE: BDY) was founded in 1985 as a
specialty pharmaceutical company and markets to niche physician specialties
in the U.S. and 38 international markets. Bradley's success is based on the
strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic
brands, Enhances these brands with line extensions and improved
formulations and Grows the products through promotion, advertising and
selling activities to optimize life cycle management. Bradley
Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical
therapies for dermatology and podiatry; Kenwood Therapeutics, providing
gastroenterology, respiratory and other internal medicine brands; and A.
Aarons, which markets authorized generic versions of Doak and Kenwood
therapies.


Important announcement:


July 26-30, 2006 - Doak Dermatologics will be exhibiting at the Summer
Meeting of the American Academy of Dermatology, held in San Diego, CA.


August 7-10, 2006 - Doak Dermatologics will be exhibiting at the American
Podiatric Medical Association, held in Las Vegas, NV.


Daniel Glassman will present at the RBC's Healthcare Conference, to be
held in New York City, December 12-14, 2006.


Daniel Glassman will present at the Raymond James & Associates 28th
Annual Institutional Investors Conference, to be held at the Hyatt
Regency Grand Cypress in Orlando, FL., March 4-7, 2007.


Bradley Pharmaceuticals, Inc.

bradpharm